Showing results (951-960 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 15, 2021
Effectiveness of cetuximab as preemptive postsurgical therapy for oral squamous cell carcinoma patients with major risk: a single-center retrospective cohort studyChonji Fukumoto, Yuta Sawatani, Ryo Shiraishi, et al.
Investigational New Drugs|January 17, 2021
Gut microbiota homeostasis restoration may become a novel therapy for breast cancerZhi-Peng Feng, Hong-Yi Xin, Ze-Wei Zhang, et al.
Investigational New Drugs|January 19, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsGeorgina Meneses-Lorente, Darren Bentley, Elena Guerini, et al.
Investigational New Drugs|January 28, 2021
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapyToni K Choueiri, Michael B Atkins, Tracy L Rose, et al.
Investigational New Drugs|January 21, 2021
Advances in anti-BRAF therapies for lung cancerGiandomenico Roviello, Alberto D'Angelo, Marianna Sirico, et al.
Investigational New Drugs|January 12, 2022
IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasisXing Lv, Qi Zhao, Yanqun Dong, et al.
Investigational New Drugs|January 13, 2022
Biological evaluation of complexes of cyclopentadienyl M(CO)3+ (M = Re, 99mTc) with high blood-brain barrier penetration potential as brain cancer agentsB Mavroidi, A Kaminari, K Makrypidi, et al.
Investigational New Drugs|January 13, 2022
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort studyHayato Kawachi, Motohiro Tamiya, Kinnosuke Matsumoto, et al.
Investigational New Drugs|January 11, 2022
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine modelAntônio Bruno Alves-Silva, Bruna Alves Fenerich, Natasha Peixoto Fonseca, et al.
Investigational New Drugs|January 1, 2022
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancerBo Mi Ku, Jae Yeong Heo, Jinchul Kim, et al.
Pageof 372